Clinical trials: Schizophrenia Relapse
Schizophrenia
Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia
There is accumulating experimental evidence to suggest the role of essential fatty acids (EFA) in neuronal migration, pruning and synaptic plasticity.
- Trial name
- OFFER (NCT02210962)
- Testing
- essential fatty acids, olive oil
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Lodz
Patients Diagnosed With Severe Mental Illness
From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management
The purpose of this study is to determine the benefit and impact on relapse prevention,adherence to treatment and general health indices of participation in psycho-eduational group intervention among psychiatric patients with…
- Trial name
- NCT00192751
- Testing
- Psychoeducational group sessions
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Rambam Health Care Campus
Schizoaffective Disorder
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT01193153
- Testing
- paliperidone palmitate
- Where
- 80 sites in United States, Bulgaria and 6 more
- Volunteers
- 667 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia Spectrum and Other Psychotic Disorders
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
The primary objective of this single-center multi-site retrospective chart review is to determine if paliperidone palmitate and/or risperidone long-acting injection can decrease the number of psychiatric relapses following their…
- Trial name
- NCT03390712
- Testing
- Paliperidone Palmitate, Risperidal Consta, Antipsychotic
- Where
- 4 sites in Canada
- Volunteers
- 328 people
- Sponsor
- Réseau de Santé Vitalité Health Network
Nicotine Dependence, Schizophrenia
Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia
After successfully quitting smoking, smokers with schizophrenia are vulnerable to relapse shortly after discontinuation of treatment.
- Trial name
- NCT01576640
- Testing
- NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Risperidone Maintenance Treatment in Schizophrenia
This study set out to determine the duration of maintenance treatment with therapeutic risperidone dose in schizophrenia. In a multi-center, open label, randomized, controlled study design, patients with schizophrenia who were…
- Trial name
- NCT00848432
- Testing
- risperidone
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Capital Medical University
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis
Mindfulness Intervention and Relapse in Psychosis
Practicing mindfulness is popular and well-accepted for its benefits in improving mental and physical health. In particular, its benefits in promoting resilience to stress and well-being have been shown in studies involving…
- Trial name
- NCT04060498
- Testing
- Mindfulness intervention, Psychoeducation intervention
- Where
- Hong Kong
- Volunteers
- 152 people
- Sponsor
- The University of Hong Kong
Schizophrenia Relapse
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
- Trial name
- NCT03019887
- Testing
- reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
- Volunteers
- 139 people
- Sponsor
- Juntendo University
Schizophrenia
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
- Trial name
- NCT00228462
- Testing
- Seroquel (quetiapine)
- Where
- 5 sites in Bulgaria, Poland
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Relapse Schizophrenia
A RCT Study in Schizophrenia Relapse Prevention
THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH…
- Trial name
- NCT01885923
- Testing
- ITAREPS
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Prague Psychiatric Center
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mania (Neurotic)
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode.
- Trial name
- NCT03383874
- Testing
- Probio-Tec BG-VCap-6.5
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Relapse in Schizophrenia
Seroquel XR in the Long Term Treatment of Schizophrenia
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
- Trial name
- SereNIS (NCT01202617)
- Where
- 61 sites in Hungary
- Volunteers
- 1,606 people
- Sponsor
- AstraZeneca
Schizophrenia
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
- Trial name
- NCT00946985
- Testing
- paliperidone palmitate, oral risperidone
- Where
- 72 sites in United States, Brazil and 10 more
- Volunteers
- 163 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenic Disorders
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
The study is a randomized clinical trial investigating the efficacy of a comprehensive psychological intervention for the treatment of first episode schizophrenia
- Trial name
- NCT00161408
- Testing
- cognitive behavioural therapy, psychoeducation
- Where
- 5 sites in Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen
Schizophrenia
Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia
Information Technology-aided Program of Relapse Prevention in Schizophrenia (ITAREPS) will decrease the number of hospitalizations in patients with schizophrenia or schizoaffective disorder who are treated in the outpatient…
- Trial name
- NCT00712660
- Testing
- antipsychotic dose increase, no intervention
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Prague Psychiatric Center
Schizophrenia Relapse Prevention
Seroquel XR in Schizophrenia Relapse Prevention
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
- Trial name
- NCT00990626
- Where
- 48 sites in Hungary
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital